Monitor for initial safety and efficacy data readouts from the Phase 1 study, which could serve as a catalyst. No near-term revenue or regulatory decision is expected.
Price Chart
Executive Summary
MacroGenics announced dosing of the first patient in a Phase 1 study of MGC030, a first-in-class ADC for advanced solid tumors. This is an early clinical milestone with no financial data or regulatory catalyst disclosed, making it a routine pipeline update for a clinical-stage biotech.
Key Facts
- First patient dosed in Phase 1 study of MGC030, a first-in-class ADC targeting an undisclosed antigen in advanced solid tumors.
- Phase 1 study is open-label, multi-center, dose-escalation, dose-optimization, and cohort-expansion; enrolling up to 54 participants initially.
- MGC030 is the company's third ADC in active clinical development.
- No financial terms, revenue, EPS, guidance, or deal values were disclosed.
Financial Impact
No financial impact disclosed; early-stage clinical milestone with no revenue or cost figures provided.
Risk Factors
- Preclinical results may not translate to clinical efficacy or safety.
- Early-stage clinical trials have high failure rates, especially for first-in-class ADCs.
- No disclosed financial runway or partnership details to support ongoing development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382129 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $2.19 | awaiting T+60 | — | $2.19 (+0.00%) |
Oct 23, 2026 4d ago | 8-K | $2.19 | awaiting T+60 | — | $2.19 (+0.00%) |
Oct 22, 2026 5d ago | 144 | $2.25 | awaiting T+60 | — | $2.19 (−2.67%) |
Oct 15, 2026 12d ago | Press Release | $3.25 | awaiting T+60 | — | $2.19 (−32.62%) |
Jul 8, 2026 15w ago | 8-K | $4.57 $3.58 | ▼ −21.66% | ▼ −23.30% | $2.19 (−52.08%) |
Jul 2, 2026 16w ago | Press Release | $4.71 $3.80 | ▼ −19.32% | ▼ −22.33% | $2.19 (−53.50%) |
Jun 12, 2026 19w ago | Institutional Cluster | $3.96 $4.32 | ▲ +9.09% | ▲ +5.83% | $2.19 (−44.70%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.01 $4.40 | ▲ +9.73% | ▲ +5.33% | $2.19 (−45.39%) |
May 13, 2026 23w ago | 8-K | $4.16 $4.08 | ▼ −1.92% | ▼ −5.51% | $2.19 (−47.36%) |
May 12, 2026 24w ago | 8-K | $3.52 $4.01 | ▲ +13.92% | ▲ +9.54% | $2.19 (−37.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers